Cephalon's Nuvigil Jet Lag Indication Grounded By Complete Response Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Wall Street analysts question the extent to which the FDA move is a setback, given the outlook for the company's wakefulness franchise.
You may also be interested in...
Cephalon’s Nuvigil For Jet Lag Is Pulled Off The Runway; Bipolar Indication Remains On The Horizon
After dropping efforts to obtain approval of Nuvigil (armodafinil) for treatment of jet lag disorder, Cephalon is left with one possible new indication for the wakefulness drug: depression associated with bipolar disorder.
Cephalon’s Nuvigil For Jet Lag Is Pulled Off The Runway; Bipolar Indication Remains On The Horizon
After dropping efforts to obtain approval of Nuvigil (armodafinil) for treatment of jet lag disorder, Cephalon is left with one possible new indication for the wakefulness drug: depression associated with bipolar disorder.
Cephalon Looks For Growth as Nuvigil Fails Schizophrenia Trial
With sales leader Provigil slated to lose patent protection in 2012, specialty pharma also is looking beyond Nuvigil for answers.